An elegant and surprisingly easily read cohort study of mechanical destruction of platelets in ECMO circuits that parallels what we already know in pumps for full cardiopulmonary bypass. The authors propose a biomarker as a target for thrombotic modulation .
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Physiology
September 20, 2022
Plasma metabolomic profiles were examined to determine differences in social determinants of health between Black and white women. This observational study paves the groundwork for further investigation of social disparity in atheromatous disease.
June 23, 2022
This scientific statement is a granular contribution to a major cardiovascular issue, illuminating nuances of the "generally recognized as safe" (GRAS) FDA designation. One would expect the relevant Thoracic Associations in North America and Europe to contribute to this debate.
May 18, 2022
Gripping vignette of a fatal case of renocardiac pathologies. The stills from the (sadly non-contrast) CTA are most interesting.
April 5, 2022
A brief but comprehensive editorial on nuances of the links between atrial fibrillation and heart failure, apropos a trial we have commented recently on, by the Johns Hopkins team that develops the calmodulin-dependent protein kinase II inhibitor molecules
March 30, 2022
Interesting case-control study on variations of aortovascular compliance
March 4, 2022
A paper that addresses a gap in knowledge and will guide future research: of particular interest, the penultimate paragraph on The Role of Interventions.
November 19, 2021
Impressive decrease of death (by approximaltely 40% !) in 2 years from a small RCT in elective structural heart surgery for degeneration. The assumption is a benefit by improvement in right ventricular dynamics
November 1, 2021
An extremely useful and free-access update on a major vascular entity. The 'Areas of Uncertainty' is a particularly useful chapter, discussing the available technology and its current supra-renal limitations and the emerging solutions.
October 21, 2021
A large randomised double-blinded trial reporting a considerable benefit ( 0.79 HR with very small p and supporting confidence intervals) of the Boehringer SGLPT-2 inhibitor regardless of presence of formal diagnosis of diabetes.